Reaction
Neuroendocrine Tumour reporting signals
As of the last recalculation, Neuroendocrine Tumour appears in 1,407 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 279.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Octreotide Acetate | 410 | 279.0 | 282.8 |
| Everolimus | 227 | 78.5 | 78.8 |
| Everolimus Tablets | 63 | 58.1 | 58.4 |
| Lanreotide Acetate | 19 | 36.3 | 36.4 |
| Temozolomide | 24 | 17.1 | 17.1 |
| Pancrelipase | 21 | 8.2 | 8.2 |
| Teduglutide | 7 | 7.7 | 7.7 |
| Sunitinib Malate | 18 | 6.8 | 6.8 |
| Oral Semaglutide | 23 | 4.7 | 4.7 |
| Ranitidine Hydrochloride | 10 | 2.7 | 2.7 |
| Tirzepatide | 17 | 1.6 | 1.6 |